iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study.
antidiabetic drug
database research
hypoglycaemia
iGlarLixi
real-world evidence
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
19
12
2022
received:
28
10
2022
accepted:
30
12
2022
medline:
4
4
2023
pubmed:
13
1
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
To compare outcomes in adults with type 2 diabetes (T2D) suboptimally controlled with basal insulin who initiated treatment with iGlarLixi or premixed insulin. This retrospective real-world analysis was conducted using data from adults (age ≥ 18 years) with T2D in the US Optum Clinformatics database who had previously received basal insulin and newly initiated iGlarLixi or premixed insulin. Cohorts were propensity-score matched on baseline characteristics using a greedy nearest neighbour-matching algorithm, and outcomes were assessed at 12 months. Subgroup analyses were performed for those aged 65 years or older and those with a baseline HbA1c of 9% or higher. The primary endpoint was treatment persistence in the overall population. Secondary endpoints were treatment adherence, healthcare resource utilization (HRU), costs, hypoglycaemia events and change in HbA1c from baseline. Each cohort comprised 834 participants. In the overall population, treatment persistence at 12 months was statistically significantly higher for iGlarLixi versus premixed insulin: 42.5% versus 39.1%; hazard ratio 0.88; 95% confidence interval 0.778-0.998; P = .0465. Adherence and HbA1c reduction were similar between groups, whereas hypoglycaemia events, HRU and costs were numerically lower for iGlarLixi. Outcomes in both the age 65 years or older subgroup and in those with an HbA1c of 9% or higher were consistent with those for the overall population. In this observational study in people with T2D suboptimally controlled on basal insulin, once-daily iGlarLixi was an effective treatment alternative to premixed insulin with significantly higher treatment persistence, similar adherence and HbA1c reduction, and numerically lower hypoglycaemia events, HRU and costs, regardless of age or baseline HbA1c.
Substances chimiques
Insulin
0
Insulin Glargine
2ZM8CX04RZ
Hypoglycemic Agents
0
Glycated Hemoglobin
0
Insulin, Regular, Human
0
Blood Glucose
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1249-1260Subventions
Organisme : Sanofi
Informations de copyright
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
International Diabetes Fund. IDF Diabetes Atlas. 2021. 10th edition. https://diabetesatlas.org/atlas/tenth-edition/. Accessed March 2022.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513-1530.
Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41(5):963-970.
Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
Duckworth WC, Abraira C, Moritz TE, et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA diabetes trial. J Diabetes Complications. 2011;25(6):355-361.
Muller DC, Elahi D, Tobin JD, Andres R. Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution. Aging. 1996;8(1):13-21.
Rosenthal M, Doberne L, Greenfield M, Widstrom A, Reaven GM. Effect of age on glucose tolerance, insulin secretion, and in vivo insulin action. J Am Geriatr Soc. 1982;30(9):562-567.
Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab. 2003;284(1):E7-E12.
Freeman J. Management of hypoglycemia in older adults with type 2 diabetes. Postgrad Med. 2019;131(4):241-250.
Basu R, Dalla Man C, Campioni M, et al. Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes. 2006;55(7):2001-2014.
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417.
Mauricio D, Meneghini L, Seufert J, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19(8):1155-1164.
Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426.
Garber AJ. Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient. Diabetes Obes Metab. 2009;11:14-18.
Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006;66(1):31-49.
Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 2009;52(10):1990-2000.
Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab. 2006;8(1):58-66.
Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005;22(4):374-381.
Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260-265.
Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab. 2006;8(4):448-455.
Coscelli C, Calabrese G, Fedele D, et al. Use of premixed insulin among the elderly: reduction of errors in patient preparation of mixtures. Diabetes Care. 1992;15(11):1628-1630.
Centers for Medicare & Medicaid Services. Press release: CMS launches groundbreaking model to lower out of pocket expenses for insulin. 2020. https://www.cms.gov/newsroom/press-releases/cms-launches-groundbreaking-model-lower-out-pocket-expenses-insulin. Accessed April 2022.
Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med. 2008;149(8):549-559.
Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299-1307.
Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications. 2012;26(5):399-406.
Jude EB, Trescoli C, Emral R, et al. Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: a retrospective UK cohort study. Diabetes Obes Metab. 2021;23(4):929-937.
Satoh J, Andersen M, Bekker Hansen B, et al. Clinical inertia in basal insulin-treated patients with type 2 diabetes - results from a retrospective database study in Japan (JDDM 43). PLoS One. 2018;13(9):e0198160.
Rosenstock J, Emral R, Sauque-Reyna L, et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care. 2021;44(10):2361-2370.
SOLIQUA prescribing information. 2021. https://products.sanofi.us/soliqua100-33/soliqua100-33.pdf.
Pantalone KM, Heller C, Lajara R, et al. Initiation of iGlarLixi vs. basal-bolus insulin in adults with type 2 diabetes, those aged ≥65 years, and those with glycated hemoglobin A1C ≥9% advancing from basal insulin therapy: the SoliComplex real-world study. Manuscript accepted. Diabetes Spectrum. 2022.
Polonsky WH, Giorgino F, Rosenstock J, et al. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. Diabetes Obes Metab. 2022;24(12):2364-2372.
Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the global attitudes of patients and physicians in insulin therapy study. Diabetes Obes Metab. 2012;14(12):1081-1087.
American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al. 13. Older adults: Standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S216-S229.
American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140-S157.